Background
==========

It is well recognized that highly active antiretroviral therapy (HAART) can control HIV/AIDS and prolong patient's life. However, HAART is associated with drug toxicity, drug resistant, and patient\'s affordability. Therefore, developing an effective therapeutic vaccine that could induce HIV-specific immune responses may provide a solution to reduce the need of antiretroviral therapy. Adenovirus based vaccines have been extensively evaluated as a vaccine vehicle for HIV/AIDS and a variety infectious diseases, however, it has been a major concern that anti-Ad5 neutralizing antibodies in general population or after the first dose of immunization can hinder the its practical application. The idea of using less prevalent adenovirus serotypes lack of long-term safety record including oncogeneicity. Moreover, any adenovirus serotype will inevitablely induce neutralizing antibodies after one single use which render the strategy of using more serotypes infeasible.

Methods
=======

In this study, we explored a novel "one-size-fits-all" strategy, namely AVIP (Adenoviral Vector Infected PBMC), to circumvent the attenuated efficacy of Ad-based vaccines due to anti-Ad immunity.

Results
=======

We demonstrated that this AVIP strategy can elicit SIV-specific responses in both Ad5-seropositive and Ad5-seronegative macaques. Interestingly, comparable SIV-specific but weaker Ad5-specific responses were elicited in Ad5-seronegative monkeys received AVIP immunization as compared to direct injection of Ad5-SIV vaccines. Then a cohort of Ad5-seropositive SIVmac239-infected monkeys received AVIP immunization with Ad5 vectors expressing SIVmac239 Gag, Pol and Env with HAART. After therapeutic immunization, SIV-specific response was induced in vaccinated monkeys whereas a slower responses were observed in non-vaccinated monkeys. The functional immunological profiles were also being detected, and we are also monitoring whether this immunological benefit would afford a virological benefit.

Conclusion
==========

Our goal is to further develop the AVIP strategy as a simple but practically effective method for repeated delivery of Ad5-based vaccines in humans for HIV and other diseases.
